Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.7k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • A Offline
    A Offline
    AaBforever
    wrote on sidst redigeret af
    #416

    Men spændende hvordan US ender ud i aften.

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #417

      luk i 1046

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #418

        God morgen. 🙂

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #419

          Fra SA årsregnskab

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #420

            Tisotumab Vedotin Program Highlights

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #421

              Planned Pivotal Trial: Seattle Genetics and Genmab plan to advance tisotumab vedotin into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and could support registration under the FDA’s accelerated approval regulations. The trial is expected to begin in the first half of 2018.

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #422

                Expanding Clinical Development Program: Seattle Genetics and Genmab plan to initiate in 2018 a phase 2 trial of tisotumab vedotin as part of a combination regimen in women with first-line metastatic cervical cancer. In addition, a phase 2 trial is expected to begin in 2018 to evaluate tisotumab vedotin monotherapy in a range of other solid tumor types.

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #423

                  Ikke nyt men bare en bekræftigelse

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #424

                    Tak for info Sukker. 🙂

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #425

                      Udover deres BCMA ADC med GSK går de yderligere efter BCMA med denne:

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #426

                        AACR Presence: Data from multiple research and early clinical abstracts will be featured at the American Association for Cancer Research (AACR) annual meeting being held April 14-18, 2018. Included will be preclinical data on SEA-BCMA, a novel empowered antibody using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology. SEA-BCMA is expected to advance into a phase 1 clinical trial for multiple myeloma during 2018.

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #427

                          SA er ude nogen tvivl det mest succesfulde ADC selskab, så godt det er her Genmabs satsede på ADC - det giver trods alt en stor tiltro 🙂

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JKY_VH
                            wrote on sidst redigeret af
                            #428

                            tak Sukkeralf og god morgen

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #429

                              Fidelity still likes Genmab https://www.reuters.com/article/europe-stocks/live-markets-fidelity-sees-value-in-european-drugmakers-tech-stocks-idUSL8N1PW6GT

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bibob
                                wrote on sidst redigeret af
                                #430

                                God morgen. 🙂 og tak Sukkeralf og E L.

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bibob
                                  wrote on sidst redigeret af
                                  #431

                                  Håber vi kan bevare 1040 som bund. Men desværre nok ingen stigning uden nyheder. ( gode )

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #432

                                    En partneraftale er velkommen og en god 2018 guiding m.h.t Darzalex salg.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #433

                                      NBI steg pænt i går efter luk, så måske lidt håb athente fra det generelle marked

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #434

                                        Seattle Genetics (SGEN) Q4 2017 Results - Earnings Call Transcript - with prominent mention and some further colour on tisotumab vedotin - https://seekingalpha.com/article/4143833-seattle-genetics-sgen-q4-2017-results-earnings-call-transcript?part=single

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #435

                                          Vi har set vedvarende positivt nettokøb fra A/B - gruppen på det seneste. Det hjælper i hvert fald altid på mit humør. 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger